CoChat
Sign Up
Cited by 2vaccines and immunoinformatics approachesTuberculosis Research and EpidemiologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Bioinformatics Analysis and Immunogenicity Assessment of the Novel Multi‐Stage DNA Vaccine W541 Against Mycobacterium Tuberculosis

Open access
Yang, Yourong, Xue, Yong, Wang, Xiaoou, Wang, Lan, Wang, Jie, Zhang, Junxian, Liu, Yinping, Liang, Yan, Wu, Xueqiong·2024·Immunity, Inflammation and Disease
DOI 10.1002/iid3.70074PMC PMC11590035

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Vaccination is one of the effective measures to prevent latent tuberculosis infection (LTBI) from developing into active tuberculosis (TB). Applying bioinformatics methods to pre‐evaluate the biological characteristics and immunogenicity of vaccines can improve the efficiency of vaccine development. Objectives: To evaluate the immunogenicity of TB vaccine W541 and to explore the application of bioinformatics technology in TB vaccine research. Methods: This study concatenated the immunodominant sequences of Ag85A, Ag85B, Rv3407 , and Rv1733c to construct the W541 DNA vaccine. Then, bioinformatics methods were used to analyze the physicochemical properties, antigenicity, allergenicity, toxicity, and population coverage of the vaccine, to identify its epitopes, and to perform molecular docking with MHC alleles and Toll‐like receptor 4 (TLR4) of the host. Finally, the immunogenicity of the vaccine was evaluated in animal experiments. Results: The W541 vaccine protein is a soluble cytoplasmic protein with a half‐life of 1.1 h in vivo and an instability index of 45.37. It has good antigenicity and wide population coverage without allergenicity and toxicity. It contains 138 HTL epitopes, 73 CTL epitopes, 8 linear and 14 discontinuous B cell epitopes, and has a strong affinity for TLR4. Immune simulations have shown that it can effectively stimulate innate and adaptive immune responses. Animal experiments confirmed that the W541 DNA vaccine could effectively activate Th1‐ and Th17‐type immune responses, producing high levels of IFN‐γ and IL‐17A, but could not significantly increase antibody levels. Conclusion: The W541 DNA vaccine can induce strong cellular immune responses. However, further optimization of the vaccine design is needed to make the expressed protein more stable in vivo. Bioinformatics analysis could reveal the physicochemical and immunological information of vaccines, which is critical for guiding vaccine design and development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/iid3.70074

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 97

  1. 10.1183/13993003.01245-2015 · DOI
  2. 10.1371/journal.pmed.1002152 · DOI · Paper page
  3. 10.1080/14760584.2019.1704263 · DOI
  4. 10.1056/NEJMoa1803484 · DOI
  5. 10.1136/bmjgh-2023-012306 · DOI
  6. 10.1016/j.vaccine.2023.03.015 · DOI
  7. 10.3748/wjg.v23.i2.306 · DOI
  8. 10.1158/1940-6207.CAPR-22-0217 · DOI
  9. 10.1016/j.ymthe.2022.12.017 · DOI
  10. 10.1001/jamaoncol.2022.5143 · DOI
  11. 10.1136/jitc-2023-008067 · DOI
  12. 10.1038/s41467-024-50880-2 · DOI
  13. 10.1615/CritRevEukarGeneExpr.v22.i3.10 · DOI
  14. 10.1016/j.micpath.2017.08.040 · DOI
  15. 10.3389/fimmu.2014.00321 · DOI
  16. 10.1016/j.vaccine.2008.06.066 · DOI
  17. 10.1111/1574-695X.12008 · DOI
  18. 10.3892/mmr.2016.5364 · DOI
  19. 10.1016/j.vaccine.2017.05.083 · DOI
  20. 10.3389/fimmu.2022.876579 · DOI
  21. 10.1155/2012/563838 · DOI
  22. 10.1016/j.molimm.2014.06.007 · DOI
  23. 10.3389/fimmu.2022.1087015 · DOI
  24. 10.3389/fimmu.2021.673532 · DOI
  25. 10.1093/cid/cix834 · DOI
  26. 10.1586/14760584.2014.929947 · DOI
  27. Wajja A., 2023, Safety and Immunogenicity of ChAdOx1 85A Prime Followed by MVA85A Boost Compared With BCG Revaccination Among Ugandan Adolescents Who Received BCG at Birth: A Randomised, Open‐Label Trial, Lancet Infectious Diseases, 24, 285–296
  28. 10.3390/ijms24087439 · DOI
  29. 10.3390/vaccines8040652 · DOI
  30. 10.1186/s13063-017-2354-0 · DOI
  31. 10.1016/j.eclinm.2020.100313 · DOI
  32. 10.3390/vaccines10122164 · DOI
  33. 10.1046/j.1365-2958.1999.01549.x · DOI
  34. 10.1016/j.tube.2003.12.004 · DOI
  35. 10.1002/1522-2683(200108)22:14<2936::AID-ELPS2936>3.0.CO;2-S · DOI
  36. 10.1371/journal.pone.0005590 · DOI
  37. 10.1016/j.vaccine.2011.07.144 · DOI
  38. 10.1080/08916934.2018.1546291 · DOI
  39. 10.3389/fimmu.2023.1110843 · DOI
  40. 10.1128/CVI.00271-15 · DOI
  41. 10.1111/sji.12160 · DOI
  42. 10.3389/fimmu.2020.00442 · DOI
  43. 10.3389/fimmu.2017.00278 · DOI
  44. 10.2147/ITT.S241064 · DOI
  45. 10.1089/cmb.2019.0062 · DOI
  46. 10.1007/s00894-014-2278-5 · DOI
  47. 10.1038/nmeth.1701 · DOI · Paper page
  48. 10.1016/j.ab.2009.07.046 · DOI
  49. 10.1186/1471-2105-8-4 · DOI
  50. 10.1371/journal.pone.0073957 · DOI
  51. 10.1093/nar/gkl164 · DOI
  52. 10.1093/bioinformatics/11.6.681 · DOI
  53. 10.1093/nar/gkm290 · DOI · Paper page
  54. 10.1093/protein/9.1.37 · DOI
  55. 10.1093/nar/gky949 · DOI · Paper page
  56. 10.1016/j.jmb.2007.05.022 · DOI
  57. 10.1186/1471-2105-9-514 · DOI
  58. 10.1186/1471-2105-11-568 · DOI
  59. 10.1186/1745-6150-8-30 · DOI
  60. 10.1155/2013/263952 · DOI
  61. 10.1093/bib/bbaa259 · DOI
  62. 10.1038/srep42851 · DOI
  63. 10.1093/bioinformatics/btv639 · DOI
  64. 10.1371/journal.pcbi.1003266 · DOI
  65. 10.1186/1471-2105-7-153 · DOI
  66. 10.1371/journal.pone.0009862 · DOI
  67. Michael R., 2017, Molecular Cloning: A Laboratory
  68. R.MichaelandJ. S.GreenMolecular Cloning: A Laboratory Manual (Fourth Edition): Three‐Volume Set.2012.
  69. 10.1007/s12026-022-09284-x · DOI
  70. 10.1080/14760584.2017.1306441 · DOI
  71. 10.3389/fimmu.2020.00283 · DOI
  72. 10.3389/fimmu.2024.1457327 · DOI
  73. 10.3390/vaccines11050955 · DOI
  74. 10.1084/jem.20051106 · DOI
  75. 10.1126/science.1108003 · DOI
  76. 10.1084/jem.20052442 · DOI
  77. 10.1128/MCB.20.22.8458-8467.2000 · DOI
  78. Khamsri B., 2006, Effects of Lysine to Arginine Mutations in HIV‐1 Vif on Its Expression and Viral Infectivity, International Journal of Molecular Medicine, 18, 679
  79. 10.1126/science.aaw4912 · DOI
  80. 10.1080/20477724.2017.1351080 · DOI
  81. 10.1007/s00018-020-03656-y · DOI · Paper page
  82. 10.1038/s41467-021-23683-y · DOI · Paper page
  83. 10.1371/journal.pone.0273517 · DOI
  84. 10.1080/15548627.2019.1658436 · DOI
  85. 10.1097/00001432-200306000-00004 · DOI
  86. 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6 · DOI
  87. 10.1016/j.smim.2020.101431 · DOI
  88. 10.1016/j.tube.2016.10.002 · DOI
  89. 10.1111/j.1469-0691.2009.03104.x · DOI
  90. 10.1016/S2213-2600(18)30077-8 · DOI
  91. 10.1172/JCI142014 · DOI
  92. 10.3389/fimmu.2022.840610 · DOI
  93. 10.4049/jimmunol.167.12.6991 · DOI
  94. 10.4161/hv.23229 · DOI
  95. 10.1016/j.imbio.2022.152201 · DOI
  96. 10.4049/jimmunol.165.12.7088 · DOI
  97. 10.1128/iai.62.9.3679-3687.1994 · DOI

Metadata

Authors
Yang, Y., Xue, Y., Wang, X., Wang, L., Wang, J., Zhang, J., Liu, Y., Liang, Y., & Wu, X.
Affiliations
Chinese PLA General Hospital (CN)
Corresponding author
  • Liang, Yan
  • Wu, Xueqiong
ORCID
Venue
Immunity, Inflammation and Disease
Publisher
Wiley
Published
2024-11
Volume
12
Issue
11
Pages
e70074-e70074
ISSN
2050-4527 (ISSN-L)
DOI
10.1002/iid3.70074
PMC
PMC11590035
OpenAlex
W4404717200
Cited by
2
References
2
Citations by year
2026: 1 · 2025: 1
FWCI
0.27
Type
journal article
Language
en
Open access
Licence
Locations
  • Immunity Inflammation and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
General Hospital of People’s Liberation Army
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
tuberculosis vaccine, DNA vaccine, Mycobacterium tuberculosis, Ag85A, Ag85B, immunogenicity, epitope prediction, B-cell epitopes, CTL epitopes, TLR4, MHC binding, Th1/Th17 response, latent tuberculosis infection, vaccine design
MeSH terms
Immunogenicity, Vaccine, Animals, Antigens, Bacterial, Female, Humans, Mycobacterium tuberculosis, Tuberculosis, Epitopes, T-Lymphocyte, Epitopes, B-Lymphocyte, Computational Biology, Vaccines, DNA, Tuberculosis Vaccines, Mice, Molecular Docking Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review